Cornelis Kruif - Merus BV CTO VP

MRUS Stock

USD 47.24 1.07 2.21%

Insider

Cornelis Kruif is CTO VP of Merus BV

Age	60
Phone	31 30 253 8800
Web	https://www.merus.nl

Merus BV Management Efficiency

The company has return on total asset (ROA) of (0.2747) % which means that it has lost $0.2747 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4288) %, meaning that it created substantial loss on money invested by shareholders. Merus BV's management efficiency ratios could be used to measure how well Merus BV manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Merus BV to Peers

Predict price of Merus BV

Merus BV currently holds 9.91 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Merus BV has a current ratio of 6.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Merus BV's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Roger Bakale	Kura Oncology	N/A
	Tanya MS	Replimune Group	53
	Guizhong Liu	Adagene	54
	Man MBA	Adagene	48
	Marni Kottle	Kronos Bio	N/A
	Kevin Capps	Crinetics Pharmaceuticals	N/A
	Crystal Mercado	Acrivon Therapeutics, Common	N/A
	Kristina Masson	Acrivon Therapeutics, Common	44
	Jeff Fairman	Vaxcyte	60
	Charles Newton	Lyell Immunopharma	53
	Chris MBA	Crinetics Pharmaceuticals	N/A
	Daniel Faga	AnaptysBio	45
	Rex CFA	Anebulo Pharmaceuticals	64
	Stephanie Yao	Kronos Bio	N/A
	Jc MD	Adagene	60
	Anjali Ganguli	Syndax Pharmaceuticals	47
	ScD Swartz	Sutro Biopharma	N/A
	Esq JD	Kura Oncology	58
	Richard Heyman	Syndax Pharmaceuticals	68
	BCh BM	Kronos Bio	40
	Adriana MBA	Crinetics Pharmaceuticals	N/A

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Merus NV is traded on NASDAQ Exchange in the United States. Merus BV (MRUS) is traded on NASDAQ Exchange in USA. It is located in Uppsalalaan 17, Utrecht, Netherlands, 3584 CT and employs 260 people. Merus BV is listed under Biotechnology category by Fama And French industry classification.

Management Performance

	Return On Equity	-0.43
	Return On Asset	-0.27

Merus BV Leadership Team

Elected by the shareholders, the Merus BV's board of directors comprises two types of representatives: Merus BV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merus. The board's role is to monitor Merus BV's management team and ensure that shareholders' interests are well served. Merus BV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merus BV's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Ashley PharmD, Senior Affairs
	Kathleen Farren, IR Officer
	Gregory Perry, Chief Officer
	Hennie Hoogenboom, CoFounder Advisor
	Alexander Bakker, Chief VP
	Peter JD, Company EVP
	Cecilia Geuijen, Chief VP
	Jillian Connell, VP Communications
	Sven MD, President, CEO
	Cornelis Kruif, CTO VP
	Hui Liu, Chief Business Officer and Head of Merus U.S., Executive Vice President
	Harry Shuman, Chief Officer
	Andrew MD, Consultant
	Audrey Bergan, Chief Officer
	Shannon Campbell, Executive Officer

Merus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merus BV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.43
	Return On Asset	-0.27
	Operating Margin	(9.70) %
	Current Valuation	2.81 B
	Shares Outstanding	69.09 M
	Shares Owned By Insiders	2.03 %
	Shares Owned By Institutions	97.97 %
	Number Of Shares Shorted	6.64 M
	Price To Earning	(4.47) X
	Price To Book	5.15 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Merus Stock Analysis

When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC